news
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial
The pharma company’s injectable GLP-1/GIP receptor agonist CT-388 is an important element of its weight loss strategy and also delivered benefits for pre-diabetic patients.
List view / Grid view
Big Pharma
news
Genentech doubles investment in North Carolina manufacturing facility
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
news
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
news
Johnson & Johnson’s Caplyta demonstrates phase III promise for depression
Combination therapy comprising of an antidepressant and small molecule drug significantly boosted remission rates in adults with major depressive disorder.
news
Teva’s migraine biologic Ajovy marks phase III progress for paediatric patients
The monoclonal antibody could provide a new preventative treatment option for episodic migraines, new late-stage data suggests.
news
AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
news
Sanofi wins EU approval for its type 1 diabetes biologic Teizeild
The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe.
news
Novartis to site its fourth US radioligand manufacturing facility in Florida
The new Winter Park plant advances the pharma company’s $23 billion commitment to enhance its US radioligand medicine manufacturing capabilities.
news
Endotoxins research supports recombinant reagent use for pharma QC
Replacing LAL reagents with animal-free alternatives addresses industry commitments to improve QC practices’ ethics and sustainability.
news
AstraZeneca hires Rick Suarez to lead its biopharma efforts in the US
His appointment comes as the pharma company AstraZeneca seeks to hit $80 billion revenue target by 2030.
news
Lilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal
The deal brings it access to oral therapies targeting inflammatory-mediated conditions, including cardiometabolic, neurodegenerative and autoimmune diseases.
news
US oral GLP-1 first as Novo Nordisk launches Wegovy pill
The obesity drug’s new formulation gains an important opportunity to define the market before regulators finish assessing Lilly’s rival orforglipron.
news
Novartis chromatography study shows downstream purification benefits
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
news
J&J’s Rybrevant-Lazcluze combination wins FDA first in lung cancer
US approval of the subcutaneous therapy provides a novel chemotherapy-free frontline option in EGFR-mutated NSCLC.
news
CHMP recommends cancer medicines by SFL Pharmaceuticals and Serum Life Science Europe
The EMA’s human medicines committee also recommended approval of drugs by GSK, Moderna, STADA, Lupin Europe and Cytokinetics.
